Thursday, Jan 28 2021 | Time 05:22 Hrs(IST)
image
  • UEFA confirms plans to conduct Euro 2020 in 12 cities, will decide on spectators in April
  • Nine policemen wounded in Lebanon's Tripoli from grenade blasts during protests
  • Three arrested from UP for robbery in Thane
  • Six die in separate road accidents at Shimla
  • Covid-19: 123 new cases detected in Nashik
  • One held with mandul snake in Nashik
  • R-Day violence: FIR against Yogendra Yadav, Rakesh Tikait, Medha Patkar, 34 others
  • Over 50 peopled killed in traffic accident in Cameroon - Reports
  • R-Day violence: Delhi CP warns strict action against perpetrators
Business Economy


Swiss Rockets AG announces the founding of ROCKETVAX for the development of a next-generation SARS-CoV-2 vaccine

BASEL, Switzerland, Nov 10, 2020 /PRNewswire/ -- The rapid development of an effective and safe vaccine against SARS-CoV-2 is a top priority for Swiss Rockets AG.

A Basel-based subsidiary, RocketVax AG, was founded to utilize innovative Swiss technologies and expertise to achieve this goal.



"The development of a SARS-CoV-2 vaccine might be more complex than anticipated, and the first generation of vaccines may not provide the long-lasting, high-level protection that will be needed to end the many negative consequences of the global SARS-CoV-2 pandemic. A number of leading SARS-CoV-2 vaccine candidates use other viruses, such as adenoviruses tagged with just one coronavirus protein, particularly the spike protein which is required for the virus to enter cells. However, it is unlikely that these vaccines will induce strong and lasting protection against SARS-CoV-2. We believe that it is important to develop vaccines that cover as many SARS-CoV-2 proteins as possible but without any pathogenic potential", says Dr. Vladimir Cmiljanovic, Chairman and CEO of Swiss Rockets.



Prof. Dr. Thomas Klimkait, Virologist at the University of Basel and Project Leader of Preclinical Development at RocketVax, explains: "As an innovative next-generation vaccine, RocketVax is developing a complete but 'replication blocked' SARS-CoV-2 virus that presents all essential protein components in the virus particle to the human immune system." Novel methods are being utilized in the production of the active ingredient. RocketVax, in a first step, relies on ground-breaking DNA synthesis technology from the ETH spin-off Gigabases Switzerland AG. The gene sequence of the desired artificial viral genome, optimal for an immune response, is designed using high computing power and advanced DNA design algorithms. The designed genome lacks one essential virus element needed for replication. This element is provided by a human producer cell, yielding complete virus particles in the laboratory. The "artificial virus" can be made in large quantities for use as a vaccine. This technology allows the rapid production of various genome sequences, enabling vaccine production with one or mixtures of viral sequences. It also allows for incorporation of any relevant SARS-CoV-2 mutations that may arise in the future.



Foundation of RocketVax AG and acquisition of the inventor rights from the ETH spin-off Gigabases Switzerland AG



Swiss Rockets has acquired the exclusive rights to develop a SARS-CoV-2 vaccine using the breakthrough DNA synthesis technology from the ETH spin-off Gigabases Switzerland AG. The next generation of SARS-CoV-2 virus vaccines will be developed together with Gigabases and a consortium of experts from several leading Swiss universities and institutes.



For this purpose, Swiss Rockets has founded RocketVax AG in Basel and provides the necessary infrastructure with office and laboratory space as an incubator in cooperation with the Canton of Basel-City and the University of Basel. This provides RocketVax with access to the necessary biosafety laboratory. Swiss Rockets also acts as an accelerator by investing additional funds in the development of RocketVax in the medium term and is responsible for supporting RocketVax in national and international financing rounds. Also, management expertise is provided by Swiss Rockets, together with leading Swiss and international experts.



RocketVax works together with leading scientists



Prof. Marcel Tanner, Emeritus Professor of Epidemiology, Medical Parasitology and Public Health and former Director of the Swiss Tropical and Public Health Institute, will act as a chief scientific advisor. He is a leading clinical epidemiologist and a pioneer in R&D for vaccines and drugs against diseases of poverty and neglected tropical diseases.



Prof. Claudia Daubenberger, Head of Clinical Immunology at the Swiss Tropical and Public Health Institute, will support the clinical development. RocketVax will have access to an international clinical trial network to enable innovative and rapid clinical development in different human populations.



Prof. Thomas Klimkait, the virologist at the University of Basel, optimizes the virus production process and leads preclinical development.



Prof. Adrian Egli, Head of Molecular Verification and Sequencing at the University Hospital Basel, will support the preclinical and clinical development.



Dr. Matthias Christen, CEO of Gigabases Switzerland AG, a biotech company responsible for manufacturing and delivering entire DNA constructs essential for different vaccine candidates.



Prof. Beat Christen, Co-Founder of Gigabases Switzerland AG and Professor at the ETH Zurich, advises the company on DNA sequences design.



Prof. Bernd Giese from the University of Fribourg, one of the World's leading chemists, will provide DNA chemistry expertise.



Prof. Christian Münz, Co-head of the Institute for Experimental Immunology at the University of Zurich, provides expertise in new in vivo SARS-CoV-2 infection models.



Team



Board of Directors:

Dr. Jeanette Wood – Chairman, Non-executive Board member

Dr. Vladimir Cmiljanovic – Vice Chairman, Executive Board member

Dr. Natasa Cmiljanovic – Executive Board member

Dr. Thomas Ladner – Non-executive Board member

Marco Illy – Non-executive Board member



Management Team:

Dr. Vladimir Cmiljanovic – Chief Executive Officer

Dr. Natasa Cmiljanovic – Chief Operating Officer

Dr. Mohammad Johri – Chief Business Officer

Dr. Josef Künzle – Chief Quality Officer



About Swiss Rockets AG



Swiss Rockets AG, founded in 2018, is driving a paradigm shift in healthcare and innovation. Patients will benefit from new therapies developed with innovative and disruptive methods. The Swiss Rockets team combines the necessary expertise and experience to produce innovative medicines focusing on cancer and viral diseases.



The founder and CEO of Swiss Rockets AG is Dr. Vladimir Cmiljanovic, a medicinal chemist and entrepreneur with more than 15 years of experience developing cancer drugs. He is the founder of the Swiss biotech companies PIQUR and TargImmune. Together with his sister Dr. Natasa Cmiljanovic, co-founder and Scientific Director of Swiss Rockets AG, he developed cancer drugs at the University of Basel and founded and managed several biotech companies. Other co-founders are Manuel Ebner and Dr. Thomas Sander. Manuel Ebner, Managing Director at Bank of America Merrill Lynch Switzerland, is a strategic advisor to Swiss Rockets. Dr. Thomas Sander, one of the first employees of the biotech company Actelion, is a scientific advisor to Swiss Rockets.



Dr. Vladimir Cmiljanovic heads the Board of Directors of Swiss Rockets AG. Other board members are Prof. Dr. Michael N. Hall, a renowned researcher and professor at the Biozentrum of the University of Basel; Dr. Natasa Cmiljanovic, a medicinal chemist and clinical scientist with experience in the development of cancer drugs; Dr. Thomas Ladner, business lawyer, founder and co-founder of several successful start-ups and the World.Minds Foundation; and André Debrunner, financial expert and fund administrator at Northern Trust Switzerland AG.



Picture is available at AP Images (http://www.apimages.com)



For further information and to arrange interviews, please contact:



KCCC Korfmann Corporate Communications Consulting AG

Dr. Sabina Korfmann-Bodenmann

Managing Director

Zeltweg 40

8032 Zurich

T. +41 43 244 87 37

E. s.korfmann@kccc.ch



Swiss Rockets AG

Dr. Vladimir Cmiljanovic

Chief Executive Officer

Rittergasse 3

4051 Basel

T. +41 61 561 54 21

E. vladimir.cmiljanovic@swissrockets.com

www.swissrockets.com

(Disclaimer--Features may vary depending on the regions; subject to change without notice.)

More News

Hero MotoCorp to commence its operations in Mexico soon

27 Jan 2021 | 9:13 PM

Hyderabad, Jan 27 (UNI) Hero MotoCorp - the world’s largest manufacturer of motorcycles and scooters - on Wednesday announced the commencement of its operations in Mexico soon.

see more..

GHIAL to raise US $300 Mn through bond issue for Hyderabad airport expansion

27 Jan 2021 | 8:40 PM

Hyderabad, Jan 27 (UNI) GMR Hyderabad International Airport Limited (GHIAL), a subsidiary of GMR Airports Limited and a step down subsidiary of GMR Infrastructure Limited (GMR Group), on Wednesday announced that it had successfully priced an offering of US$ 300 Mn bond in the international bond market.

see more..

Successive Technologies is Now an Umbraco Gold Partner

27 Jan 2021 | 7:36 PM

NOIDA, India, Jan. 27, 2021 /PRNewswire/ -- Successive Technologies, an India-based next-gen technology services company has been awarded Gold Partner status by Umbraco. This is the highest level of partnership level and allows Successive to access exclusive Umbraco resources and do more for its Clients than before.

see more..

Canara Bank's operating profit grew by 37 29 per cent at the end of the Q3

27 Jan 2021 | 6:31 PM

Bengaluru, Jan 27(UNI) The Public sector lender Canara Bank on Wednesday, had reported an operating profit
of Rs 5382 crores at the third quarter end, a growth by over 16.02 per cent, Chairman and Managing Director of the Bank, L V Prabhakar said.

see more..
Bharti AXA General Insurance unveils Krishi Sakha App to empower farmers with apt information and protection solutions

Bharti AXA General Insurance unveils Krishi Sakha App to empower farmers with apt information and protection solutions

27 Jan 2021 | 4:52 PM

New Delhi, Jan 27 (UNI) Leading private non-life insurer Bharti AXA General Insurance on Wednesday announced the launch of its new app ‘Krishi Sakha’ to cater to the specific needs of the farmers in the country and guide them in adopting best farming practices and enhancing productivity.

see more..
image